Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers
Autore:
Avenoso, A; Facciola, G; Scordo, MG; Spina, E;
Indirizzi:
Univ Messina, Policlin Univ, Inst Pharmacol, I-98125 Messina, Italy Univ Messina Messina Italy I-98125 nst Pharmacol, I-98125 Messina, Italy
Titolo Testata:
THERAPEUTIC DRUG MONITORING
fascicolo: 5, volume: 21, anno: 1999,
pagine: 577 - 579
SICI:
0163-4356(199910)21:5<577:NEOTNA>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
OXIDATION POLYMORPHISM; O-DEMETHYLATION; PAROXETINE; METABOLISM; SPARTEINE;
Keywords:
reboxetine; CYP2D6; dextromethorphan; drug interaction;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Spina, E Univ Messina, Policlin Univ, Inst Pharmacol, Via Consolare Valeria, I-98125 Messina, Italy Univ Messina Via Consolare Valeria Messina ItalyI-98125 , Italy
Citazione:
A. Avenoso et al., "No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers", THER DRUG M, 21(5), 1999, pp. 577-579

Abstract

The effect of the new antidepressant reboxetine on the activity of the cytochrome P450 (CYP) 2D6 isoenzyme was investigated in 10 healthy volunteers using dextromethorphan as a model CYP2D6 substrate. Each volunteer receiveda single 30 mg oral dose of dextromethorphan on three different occasions separated by an interval of at least 4 weeks: a) in a control session; b) after 1 week of treatment with reboxetine, 8 mg/day; and c) after 1 week of treatment with paroxetine tan inhibitor of CYP2D6 activity) 20 mg/day. Urine was collected over the next 8 hours for the determination of the dextromethorphan/dextrorphan metabolic ratio. All subjects were classified as extensive metabolizers (EM) with a dextromethorphan/dextrorphan ratio <0.3. There were no notable changes in the urinary dextromethorphan/dextrorphan ratioin the reboxetine phase as compared to the control session. By contrast, there was a statistically significant increase in the metabolic ratio in theparoxetine phase (p < 0.001), with 4 subjects switching to poor metabolizer (PM) phenotype. These results suggest that reboxetine is unlikely to cause clinically significant interactions with substrates of CYP2D6.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 07:13:06